Literature DB >> 23621143

Surgical treatment of hypertrophic cardiomyopathy.

Sameh M Said1, Joseph A Dearani, Steve R Ommen, Hartzell V Schaff.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a clinical entity in which there is unexplained hypertrophy of the left ventricle in the absence of another cardiac or systemic etiology. Variants of HCM may include basal, midventricular, apical or diffuse types. In this review, the authors summarize the current surgical treatment and outcomes of septal myectomy in HCM. HCM is a unique primary myocardial disease characterized by hypertrophy of the myocardium. It is associated with a variety of presentations that range from asymptomatic to sudden cardiac death. Previously known as idiopathic hypertrophic subaortic stenosis, HCM is recognized as a genetic predisposition to myocardial hypertrophy. Medical treatment is the first-line therapy for patients with symptoms due to left ventricular outflow tract obstruction. However, septal myectomy continues to be an excellent treatment option for those intolerant of or unresponsive to medical therapy. In this paper, the authors review the role of surgery in HCM and the different variants of this unique disease.

Entities:  

Mesh:

Year:  2013        PMID: 23621143     DOI: 10.1586/erc.13.46

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  6 in total

1.  Surgery for hypertrophic cardiomyopathy.

Authors:  James J Wu; Michael Seco; Caroline Medi; Chris Semsarian; David R Richmond; Joseph A Dearani; Hartzell V Schaff; Michael J Byrom; Paul G Bannon
Journal:  Biophys Rev       Date:  2015-01-10

2.  Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.

Authors:  Kunal D Kotkar; Sameh M Said; Joseph A Dearani; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 3.  Targeting the sarcomere in inherited cardiomyopathies.

Authors:  Sarah J Lehman; Claudia Crocini; Leslie A Leinwand
Journal:  Nat Rev Cardiol       Date:  2022-03-18       Impact factor: 49.421

4.  Outcomes of an extended Morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy.

Authors:  Yun Liu; Yunhu Song; Ge Gao; Jun Ran; Wenjun Su; Haojie Li; Yajie Tang; Fujian Duan; Hansong Sun
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

Review 5.  Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient.

Authors:  Jacobo Moreno Garijo; Cristina Ibáñez; Juan M Perdomo; Martin D Abel; Massimiliano Meineri
Journal:  Asian Cardiovasc Thorac Ann       Date:  2021-09-24

6.  Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.

Authors:  Lei Yao; Li Li; Xiong-Jun Lu; Yan-Ling Miao; Xiao-Ning Kang; Fu-Jian Duan
Journal:  Cardiovasc Ultrasound       Date:  2016-05-17       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.